Holen Sie sich die Stockscreener-App
12.03
3.53%
-0.44
Schlusskurs vom Vortag:
$12.47
Offen:
$12.44
24-Stunden-Volumen:
6.17M
Relative Volume:
1.37
Marktkapitalisierung:
$5.95B
Einnahmen:
$4.45B
Nettoeinkommen (Verlust:
$205.00M
KGV:
30.07
EPS:
0.4
Netto-Cashflow:
$372.00M
1W Leistung:
-0.41%
1M Leistung:
-0.66%
6M Leistung:
-7.75%
1J Leistung:
-18.39%
1-Tages-Spanne:
$11.93
$12.47
1-Wochen-Bereich:
$11.83
$12.70
52-Wochen-Spanne:
$11.11
$18.80
Elanco Animal Health Inc Stock (ELAN) Company Profile
Firmenname
Elanco Animal Health Inc
Sektor
Telefon
877-352-6261
Adresse
2500 INNOVATION WAY, GREENFIELD
Vergleichen Sie ELAN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
12.03 | 5.95B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
170.90 | 77.10B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.39 | 42.45B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.73 | 20.09B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
151.82 | 15.37B | 2.24B | 385.90M | 440.10M | 3.73 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-09 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-09-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-19 | Eingeleitet | Jefferies | Buy |
| 2023-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2023-04-20 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Herabstufung | Goldman | Buy → Sell |
| 2022-07-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-18 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-28 | Herabstufung | Stifel | Buy → Hold |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-06-15 | Hochstufung | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Eingeleitet | Stifel | Buy |
| 2021-03-22 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Herabstufung | Argus | Buy → Hold |
| 2020-11-09 | Herabstufung | Barclays | Overweight → Underweight |
| 2020-08-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-08-04 | Fortgesetzt | Goldman | Buy |
| 2020-07-27 | Herabstufung | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-19 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Eingeleitet | Barclays | Overweight |
| 2019-08-26 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-23 | Eingeleitet | Guggenheim | Neutral |
| 2019-03-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-23 | Eingeleitet | UBS | Sell |
| 2019-01-15 | Eingeleitet | Argus | Buy |
| 2018-10-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Elanco Animal Health Inc Aktie (ELAN) Neueste Nachrichten
Morgan Stanley Lowers Elanco Animal Health (NYSE:ELAN) Price Target to $14.00 - MarketBeat
Elanco Animal demitasse Health Incorporated - The Branding Iron
US FDA approves Elanco's treatment for parasitic infections in dogs - AOL
Veterinary Medicine Market Is Booming Worldwide 2025-2032 | - openPR
Elanco price target lowered to $14 from $15 at Morgan Stanley - MSN
2025-01-29 | Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Shareholders to Inquire about Securities Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
Meet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal - PR Newswire
2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Connect | NYSE:ELAN | Press Release - Stockhouse Publishing
Senior, geriatric dog care focus of new industry partnership - VeterinaryPracticeNews.com
Animal Gastroesophageal Reflux Disease Market Analysis Report 2025-2030, with Profiles of Key Players Zoetis, Merck, Elanco, Ceva, BioZyme, Annamaet Petfoods, Hill's Pet Nutrition, Blue Buffalo & More - Yahoo Finance
Now Available: Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Provides Broadest[i] Parasite Protection of Its Kind - PR Newswire
Assenagon Asset Management S.A. Sells 1,369,833 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
2025-01-22 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Reach Out | NYSE:ELAN | Press Release - Stockhouse Publishing
Jim Cramer: AMD Is A 'Great' Company, Hold Onto Dow Inc. - Benzinga
UK Veterinary Medicine Market May See a Big Move | Norbrook, Merck, Elanco - openPR
Is Elanco Animal Health Incorporated (ELAN) the Most Undervalued Stock to Invest in for Under $20? - Insider Monkey
12 Most Undervalued Stocks to Invest in for Under $20 - Insider Monkey
Top animal health companies by revenue worldwide 2023 - Statista
2025-01-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
ELAN (Elanco Animal Health) Deferred Tax : $0 Mil (TTM As of Sep. 2024) - GuruFocus.com
Elanco Animal Health's SWOT analysis: stock outlook amid product challenges - MSN
ELAN (Elanco Animal Health) Long-Term Debt : $4,313 Mil (As of Sep. 2024) - GuruFocus.com
Elanco Animal Health’s SWOT analysis: stock outlook amid product challenges - Investing.com Nigeria
Companion Animal Ear Infection Treatment Market SWOT Analysis by Leading Expert: Elanco, Vetoquinol, Ceva - openPR
2025-01-15 | Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
Elanco Animal Health: Building On Success (NYSE:ELAN) - Seeking Alpha
Veterinary Vaccines Market SWOT Analysis by Leading Expert: Virbac, Elanco, HIPRA - openPR
ELAN (Elanco Animal Health) Change In Working Capital : $239 Mil (TTM As of Sep. 2024) - GuruFocus.com
2025-01-12 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect | NYSE:ELAN | Press Release - Stockhouse Publishing
Is Elanco Animal Health (ELAN) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Elanco Animal Health Incorporated (NYSE:ELAN) Stock Position Increased by Harbor Capital Advisors Inc. - MarketBeat
Elanco Animal Health (FRA:5EA) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Jan. 10, 2025) - GuruFocus.com
Elanco Animal Health (FRA:5EA) Gross Profit : €2,236 Mil (TTM As of Sep. 2024) - GuruFocus.com
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of “Hold” from Analysts - Defense World
Animal Health Business Research Report 2024-2030 Featuring Major PlayersBayer, Boehringer Ingelheim, Ceva Sante Animale, Elanco, Heska, Merck, Nutreco, Vetiquinol, Virbac, and Zoetis - Yahoo Finance
17,250 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Purchased by Everence Capital Management Inc. - Defense World
Elanco Animal Health (NYSE:ELAN) Reaches New 52-Week Low on Analyst Downgrade - Defense World
Elanco Animal Health (FRA:5EA) Other Long Term Assets : €272 Mil (As of Sep. 2024) - GuruFocus.com
Douglas Lane & Associates LLC Trims Position in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Growth Trends in the Porcine Vaccines Market, Forecast to 2028: Increasing Government Initiatives for Funding Animal Husbandry - GlobeNewswire Inc.
Elanco Animal Health (NYSE:ELAN) Sets New 1-Year Low on Analyst Downgrade - MarketBeat
2025-01-08 | Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Stockholders to Inquire about Securities Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
Elanco Animal Health (NYSE:ELAN) Takes On Some Risk With Its Use Of Debt - Simply Wall St
Versant Capital Management Inc Sells 1,241 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Stifel Nicolaus Lowers Elanco Animal Health (NYSE:ELAN) Price Target to $18.00 - MarketBeat
Veterinary Oncology Market Generated Opportunities, Future - openPR
Finanzdaten der Elanco Animal Health Inc-Aktie (ELAN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):